Neofluidics has launched the NeoPlateTM system which uses microfluidic lab-on-a-chip technology integrated into consumable well plates to drastically reduce the costs of primary drug screening. The small nanoliter volumes used provide an almost 99% reduction in screening costs while simplifying workflows. This lower cost technology has the potential to impact drug discovery by making screening more accessible to smaller pharmaceutical companies and for testing rare natural compounds. Neofluidics is headquartered in Carlsbad, California and was founded in 2014, holding two patents for their lab-on-a-chip technology across five product lines including applications in the petroleum and military industries.

1. Neofluidics Launches NeoPlate™ Technology; Can a Lower Cost of Drug Discovery
Impact the Pathway to New Drugs?
CARLSBAD, CALIFORNIA—October 10, 2015. For the past 50 years, high-throughput
screening for drug discovery has remained virtually unchanged. Robotic liquid handling
systems test large libraries of compounds for reactivity with new drug candidates using
an industry-standard disposable plate containing 96 individual liquid wells. Costs for a
typical test run of one million compounds can be as much as $10 million USD. The high
cost of screening can adversely impact testing by smaller Pharma companies, or the
testing of rare compounds with small available volumes such as those derived from
natural plant sources.
Neofluidics, an innovative California-based start-up in the growing field of microfluidics,
is hoping to reinvent the process with their NeoPlate™ system that drastically reduces the
costs of primary drug screening. Using lab-on-a-chip technology integrated into a
consumable well plate, the small nanoliter volumes used effect an almost 99% reduction
in primary screening costs, while at the same time reducing filling errors and simplifying
workflows by allowing single step dilution. The technology has been designed to work
with most existing robotic liquid handling systems making its adoption by industry a
seamless process.
“In the same way that Google transformed the Internet space by establishing a platform
technology, we think our NeoPlate™ system will transform many areas of drug research
and discovery as a true platform technology,” said Deepak Solomon, Chief Product
Engineer for Neofluidics.
The company has adapted the technology for other applications such as single-cell
analysis which features a microfluidic network of trapping chambers designed to
capture single cells from a larger, initial cell population which is useful in cancer,
immunologic, and genetic research. Another version of the technology uses microscopic
volumes for tissue organ modeling to test drug toxicity.
Neofluidics is headquartered in Carlsbad, California. Started in 2014, it holds two patents
for lab-on-a-chip technology and has five product lines, including applications in the
petroleum and military market segments. Since the launch of its NeoPlate™ well plate in
September, the company has fulfilled orders for numerous clients throughout North
America and abroad.
For more information contact:
Dr. Deepak E. Solomon, Neofluidics Chief Product Engineer
2382 Faraday Avenue, Suite 29
Carlsbad CA 92008
deepak@neofluidics.com
(806) 319-3083
www.neofluidics.com